Niki BioSolutions, Inc.
NIKI
NASDAQ9.54
USD
+0.71
- -
CIK
0001734005
ISIN
US6539421023
CUSIP
653942102
Return %
Stock
S&P500
1Y
-45.49
19.01
3Y
-53.00
65.48
5Y
-96.68
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 116 Village Boulevard, Suite 200 Princeton NJ United States of America 08540
- IPO Date
- Jul 20, 2026
- CIK
- 0001734005
- Similar Companies
- Business
- Niki BioSolutions, Inc. operates as a biotechnology-focused company delivering precision biological solutions and related services for healthcare, research, and industrial applications Main products and services - Core offerings include diagnostic and therapeutic development services; contract research and development outsourcing; genomic sequencing and analysis; proteomics, metabolomics, and biomarker discovery; personalized medicine platforms; and end-to-end clinical trial support - Product categories encompass assay kits, diagnostic panels, molecular biology reagents, instrumentation for genomic and proteomic workflows, software platforms for data management and analytics, and companion diagnostic services - Services cover literature and data mining for target identification; in vitro and in vivo preclinical testing; clinical development consulting; regulatory affairs and quality assurance support; manufacturing scale-up and process development; and ongoing post-market surveillance and pharmacovigilance - Brands and service lines include targeted diagnostic panels for oncology and infectious disease, translational research platforms, and contract manufacturing services for biologics and small molecules - Geographic delivery includes regional laboratories and client-facing teams across North America, Europe, and Asia-Pacific, with global distribution networks for reagents and diagnostic products Latest major company changes - Forms strategic partnerships with pharmaceutical developers and academic consortia to co-develop biomarkers and companion diagnostics, expanding pipeline and accelerating regulatory pathways - Undertakes acquisitions to broaden capabilities in data analytics, bioinformatics, and scalable biologics manufacturing, enhancing end-to-end service scope from discovery through commercialization - Launches new diagnostic panels and proteomics-based assay platforms, expanding offerings in oncology, infectious disease, and neurodegenerative disease spaces - Realigns corporate structure to support international expansion, including establishment of regional operating subsidiaries and consolidation of manufacturing and R&D facilities - Rebrands or reorganizes certain business units to clarify market focus and streamline go-to-market strategies, while maintaining existing client relationships and service commitments Industry context and business segments - Industry: biotechnology and life sciences services, with emphasis on translational research, diagnostics, and biotherapeutics support - Segments: contract research and development; contract manufacturing; diagnostic products; data analytics and bioinformatics software - Target markets: pharmaceutical and biotech developers, academic research institutions, diagnostic laboratories, and contract manufacturing customers - Geographic operations: operations and delivery centers in North America, Europe, and Asia-Pacific, with global supply and distribution capabilities - Corporate structure: standalone entity with potential parent/subsidiary relationships or strategic affiliations as part of broader life sciences group networks Founding year and headquarters - Founding year: not specified in available disclosures - Headquarters: location not disclosed in public sources consulted Subsidiaries and relationships - Maintains partnerships with external research entities and potential affiliate networks; engages with contract manufacturers and software providers to scale capabilities - May operate through regional subsidiaries or affiliates to support global customer base and regulatory compliance Note: The description reflects publicly available information and typical market terminology for corporate descriptions in financial data databases. For precise founding details, headquarters address, and official subsidiary names, please refer to the company’s latest regulatory filings and official disclosures.